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Nowadays, the alarming rise in multidrug-resistant microorganisms urgently demands
for suitable alternatives to current antibiotics. In this regard, antimicrobial peptides
(AMPs) have received growing interest due to their broad spectrum of activities,
potent antimicrobial properties, unique mechanisms of action, and low tendency to
induce resistance. However, their pharmaceutical development is hampered by potential
toxicity, relatively low stability and manufacturing costs. In the present study, we tested
the hypothesis that the encapsulation of the frog-skin derived AMP temporin B (TB) into
chitosan nanoparticles (CS-NPs) could increase peptide’s antibacterial activity, while
reducing its toxic potential. TB-loaded CS-NPs with good dimensional features were
prepared, based on the ionotropic gelation between CS and sodium tripolyphosphate.
The encapsulation efficiency of TB in the formulation was up to 75%. Release kinetic
studies highlighted a linear release of the peptide from the nanocarrier, in the adopted
experimental conditions. Interestingly, the encapsulation of TB in CS-NPs demonstrated
to reduce significantly the peptide’s cytotoxicity against mammalian cells. Additionally,
the nanocarrier evidenced a sustained antibacterial action against various strains of
Staphylococcus epidermidis for at least 4 days, with up to 4-log reduction in the number
of viable bacteria compared to plain CS-NPs at the end of the observational period. Of
note, the antimicrobial evaluation tests demonstrated that while the intrinsic antimicrobial
activity of CS ensured a “burst” effect, the gradual release of TB further reduced the
viable bacterial count, preventing the regrowth of the residual cells and ensuring a long-
lasting antibacterial effect. The developed nanocarrier is eligible for the administration
of several AMPs of therapeutic interest with physical–chemical characteristics analog to
those of TB.
Keywords: antimicrobial peptides, temporin B, delivery system, chitosan, nanoparticles, Staphylococcus
epidermidis
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Introduction
Over the last years, nanotechnologies have undergone a rapid
development in many different fields, including microbiology
and infectious diseases (Seil and Webster, 2012). In particu-
lar, nanostructures hold enormous potential as effective drug-
delivery systems to treat microbial infections as they exhibit
several advantages as compared to conventional antibiotic for-
mulations (Gao et al., 2011). For instance, NPs may be endowed
of an inherent antimicrobial activity that may sum/synergize
to that of the loaded antibiotic; furthermore, they often dis-
play high degree of biocompatibility, possibility to incorpo-
rate both lipophilic and hydrophilic drugs, ability to release
the loaded antimicrobial with controlled rate and continued
kinetics protecting it from degradation, while reducing its side
effects.
Nowadays, microbial resistance to antibacterial and antifun-
gal drugs has reached critical levels, invalidating the therapeutic
efficacy of a large proportion of molecules currently used in the
clinic (Alanis, 2005; Fair and Tor, 2014). In this regard, AMPs
have been repetitively proposed as a valid alternative to con-
ventional antibiotics (Lohner, 2009; Batoni et al., 2011; Yeung
et al., 2011; Aoki and Ueda, 2013; Roscia et al., 2013). They
comprise a large and diverse group of molecules with low ten-
dency to induce bacterial resistance and endowed with strong
and fast antimicrobial activity, directed also toward multi-drug-
resistant microorganisms (Zasloff, 2002; Maisetta et al., 2006;
Del Gaudio et al., 2013). Nevertheless, despite the initial enthu-
siasm for the possible use of AMPs as new class of antibiotics,
their clinical use remains limited because of their poor stability
in biological fluids, undesirable interactions with host macro-
molecules, and potential toxicity (Brogden and Brogden, 2011;
Kang et al., 2014). Because of these limitations, it is becoming
progressively clear that the use of natural peptides as such is
very unlikely to result in therapeutic applications and that pep-
tide modifications and/or development of appropriate peptide
formulations are needed to improve the stability, delivery, and
efficacy of promising molecules. In this regard, the encapsulation
of AMPs in micro–nanostructures might represent an innovative
approach to overcome the problems that still limit AMP-clinical
use, allowing stability of the encapsulated peptide, its safeguard
from proteolytic degradation, control of the pharmacokinetics,
and reduced toxicity. Such strategies are currently an emerging
and promising field of investigation (Yadav et al., 2011; Brandelli,
2012).
Chitosan is a high-molecular-weight linear polycationic
heteropolysaccharide comprising copolymers of β-1,4-linked
D-glucosamine and N-acetyl-D-glucosamine obtained by
deacetylation of its parent polymer chitin, the second most
abundant natural polymer in nature after cellulose, found in
Abbreviations: AMPs, antimicrobial peptides; ATTC, American Type Culture
Collection; CFU, Colony forming units; CS, chitosan; CS-NPs, chitosan nanopar-
ticles; DMEM, Dulbecco’s Modified Eagle Medium; MPs, microparticles; NPs,
nanoparticles; PLGA, poly (lactic-co-glycolic acid); RSI, Renine Substrate I; SPB,
Sodium phosphate buffer; TB, temporin B; TB-CS-NPs, chitosan nanoparticles
loaded with TB; TPP, sodium tripolyphosphate; TSA, tryptone soy agar; TSB,
tryptone soy broth.
the structure of a wide number of invertebrates and in the cell
walls of fungi (Duttagupta et al., 2015). CS has proved to be
biocompatible, non-toxic, biodegradable, and a safe excipient
in drug formulation over the last decades (Thanou et al.,
2001; Duttagupta et al., 2015). It also possesses mucoadhesive
properties and exerts antimicrobial activity against a broad
spectrum of microorganisms including Gram-positive and
Gram-negative bacteria, filamentous fungi and yeast (Kong
et al., 2010). All these characteristics render CS a promising
candidate for encapsulation of antimicrobial compounds and for
the development of novel nano-therapeutics to treat microbial
infections.
We have previously explored with success the possibility to
use CS-NPs as delivery systems of proteins with antibacterial
activity such as lysozyme (Piras et al., 2014). The suitability of
CS-NPs for the controlled release of AMPs was further inves-
tigated by us selecting RSI as a fluorogenic peptide model for
cationic amphiphilic peptides (Piras et al., 2015). These stud-
ies demonstrated that the CS-NPs formulation, developed in
presence of the model cationic peptide, had “core-shell” fea-
tures allowing for the linear release of the encapsulated pep-
tide, an encapsulation efficacy up to 98%, and possessed the
high cytocompatibility typical of CS based nanocarriers. Based
on these encouraging results, the present study was focused
on the application of the developed model nanocarrier, for
the loading and release of the cationic peptide TB, which
share with RSI key chemical–physical properties that have great
influence in the NPs formulation process. These include the
same positive net charge at neutral pH (+2), similar per-
cent of hydrophobic amino acids (62.5 vs. 61%) and compa-
rable dimensions (1301 vs. 1393 Da). TB belongs to a large
family of small, alpha-helical, and mildly cationic AMPs iso-
lated from amphibian skin secretions and endowed with broad
spectrum antimicrobial activity (antibacterial, antiviral, antifun-
gal and, in some cases, anti-parasitic), high cytocompatibil-
ity, and immune-modulating properties (Mangoni et al., 2005;
Mangoni, 2006). TB has previously shown a strong and fast
killing ability, especially directed against Gram-positive, multi-
drug-resistant nosocomial bacterial species (Mangoni et al.,
2008).
The antibacterial properties of the developed TB-CS-NPs
were tested against Staphylococcus epidermidis, a bacterial
species chosen as model Gram-positive bacterium, increasingly
involved in opportunistic infections in hospital settings (Gomes
et al., 2014). Appropriate experimental conditions were set
up in order to evaluate long-term killing ability of TB-CS-
NPs. We found that, beyond the intrinsic antibacterial activ-
ity of either CS-NPs or TB alone, the loaded nanocarrier
showed a potent, and prolonged bactericidal ability against var-
ious S. epidermidis strains. In addition, investigation of the
cytocompatibility of free TB vs. that of the peptide loaded
into CS-NPs, highlighted an excellent role of the nanocar-
rier in reducing the peptide’s toxicity toward mammalian
cells, thus representing a promising model for the develop-
ment of NPs-based delivery system of AMPs with therapeutic
potential.
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Materials and Methods
Materials
Chitosan (Mediummolecular weight, Mw 108 kDa (Mw/Mn 2.4),
Deacetylation Degree ∼92% (Piras et al., 2014) and sodium TPP
were purchased from Sigma–Aldrich, Milan, Italy.
Synthetic TB (LLPIVGNLLKSLL-amide) was obtained from
Peptide Specialty laboratories GmBH, Heidelberg, Germany.
Acetic acid analytical grade was purchased from Carlo
Erba, Milan, Italy. Deionized water (Milli-Q, ddH2O) was
used throughout the experiments. Micro BCATM Assay Kit
was purchased from Thermo Scientific, Rockford, IL, USA.
Mouse embryo fibroblast BALB/3T3 clone A31 (CCL-163) cell
line was purchased from ATCC, (LGC standards, Milan, Italy)
and propagated as indicated by the supplier. DMEM, 0.01 M
pH7.4 Dulbecco’s phosphate buffer saline without Ca2+ and
Mg2+, bovine calf serum, L-glutamine, and antibiotics (peni-
cillin/streptomycin) were purchased from Gibco, (Monza, Italy).
Cell proliferation reagent WST-1 was purchased from Roche
Diagnostics (Milan, Italy).
Preparation of Blank CS-NPs or TB-CS-NPs
Chitosan nanoparticles were prepared using a simple ionic gela-
tion process as described earlier (Piras et al., 2015). Briefly, CS
was dissolved in 1% (v/v) acetic acid (1 mg/ml, pH 5) and TPP
was dissolved in water (1 mg/ml); for TB-CS-NPs preparation,
200 μg of the peptide were added to the CS solution. NPs formed
spontaneously upon addition of 2 ml of TPP aqueous solution to
5 ml of the CS solution under magnetic stirring; the mixture was
stirred at room temperature for 2 h.
Nanoparticles suspensions were purified by centrifugation in
ALC R©(Milan, Italy) PK121R centrifuge at 14000 g for 30 min or
at 9000 g for 60 min, at 4◦C.
Characterization of NPs
The size distribution of the developed NPs was measured
by means of dynamic light scattering (Coulter LS230 Laser
Diffraction Particle Size Analyzer, Beckman Coulter, Nyon,
Switzerland). The Zeta-potential of the developed formulations
was evaluated using a Beckman-Coulter DelsaTM NanoC, at 25◦C
in 10 mM SPB, pH 7.4.
Evaluation of TB Loading Capacity and In
Vitro Release Kinetics of NPs
The TB content present in the supernatants obtained from TB-
CS-NPs purification was measured at 565 nm by means of Micro
BCATM protein assay. The Loading content (L) was defined as the
amount of TB per TB-CS-NPs dry weight; the encapsulation effi-
ciency was defined as the amount of TB recovered in TB-CS-NPs
compared to the total amount of peptide used in the formulation
protocol.
Purified TB-loaded CS-NPs were re-dispersed in 1 ml of SPB
pH 7.4 (300μg/ml) and placed into test tubes at 37◦C undermag-
netic stirring. At appropriate intervals, samples were centrifuged
at 14000 g 4◦C for 30 min, the supernatants were collected and
replaced by 1 ml of fresh medium. The amount of TB released
from the CS-NPs was evaluated by means of Micro BCATM pro-
tein assay. All CS-NP formulations and characterization testing
were repeated at least three times.
Biological Evaluations
Cytotoxicity Tests
Cytotoxicity evaluation of TB and TB-CS-NPs was carried out
using BALB/3T3 clone A31 mouse embryo fibroblasts cell line.
Cells were grown in complete DMEM containing 10% (v/v) calf
serum, 4 mM L-glutamine, 100 U/ml of penicillin and 100 μg/ml
of streptomycin. A subconfluent monolayer of BALB/3T3 fibrob-
lasts was washed with Dulbecco’s phosphate buffered saline,
trypsinized using a 0.25% trypsin, 1 mM EDTA solution, cen-
trifuged at 200 g for 5 min, re-suspended in growth medium
and counted. Appropriate dilution was made in order to obtain
3 × 103 cells per 100 μl of medium, the final volume present
in each well of a 96 well plate. Cells were incubated at 37◦C,
5% CO2 for 24 h until 60–70% confluence was reached. For
the determination of TB IC50 (50% inhibitory concentration,
defined as the peptide concentration at which 50% of cell death
in respect to the control is observed), cells were exposed to differ-
ent concentrations of TB (3.64–466μg/ml) dissolved in complete
DMEM. Cytotoxicity assessment of the developed nanocarriers
was performed by incubating BALB/3T3 cell line with medium
containing TB-CS-NPs (2.5, 5, and 10 mg/ml, loaded with 116.5,
233, and 466 μg/ml of TB, respectively). Cells incubated with
fresh complete DMEMwere used as control and growth medium
as blank. After 24 h of incubation, cells were analyzed for viabil-
ity with Cell Proliferation Reagent WST-1, a yellow tetrazolium
salt that is reduced to formazan only by metabolically active
cells. Briefly, cells were incubated with WST-1 reagent diluted
1:10 for 4 h at 37◦C, 5% CO2. Measurements of formazan dye
absorbance were carried out at 450 nm, with the reference wave-
length at 655 nm, by using a Bio-Rad Benchmark Microplate
Reader (Bio-Rad, Hercules, CA, USA).
Bactericidal Assays
The S. epidermidis strains used in the study included a reference
strain purchased from the ATCC (S. epidermidisATCC 35984) as
well as four clinical isolates obtained from blood cultures or cen-
tral venous catheters at the Microbiology Unit of the University
Hospital of Pisa, Italy (Brancatisano et al., 2014). The susceptibil-
ity profile of the different strains to conventional drugs is shown
in Table 1. For preparation of stock cultures, the bacterial strains
were grown in TSB (Oxoid Basingstoke, UK) at 37◦C until mid-
log phase, subdivided in aliquots, and kept frozen at −80◦C until
future use. For CFU count, serially diluted bacterial suspensions
were plated on TSA (Oxoid, Basingstoke, UK) and incubated for
48 h at 37◦C.
The antibacterial activity of the developed TB-CS-NPs was
compared to that exerted by the plain nanocarrier (CS-NPs) and
by free TB. S. epidermidis cells, growing exponentially in TSB,
were washed and re-suspended in 1 ml of SPB 10 mM, pH 7.4
at approximately 1 × 108 CFU/ml. Bactericidal assays were per-
formed in the same buffer, added with 1.25% TSB (v/v; buffer
assay). The test samples were prepared by adding 10 μl of the
bacterial suspension (1 × 106 CFU) to 90 μl of the buffer assay
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TABLE 1 | Antibiotic susceptibility profiles of the different Staphylococcus
epidermidis strains used in the study.
ATCC 35984 Se30 SeBER SeNOC SeVIC
Ciprofloxacin NT ≥8a NTb NT NT
Clindamycin ≥4 ≥8 0.5 ≤0.25 ≤0.25
Daptomycin 0.5 NT NT NT NT
Erythromycin ≥8 ≥8 ≥8 ≥8 ≤0.25
Fosfomycin NT ≤8 ≤8 ≤8 ≤8
Fusidic Acid ≤0.5 ≥32 ≤0.5 ≤0.5 ≤0.5
Gentamicin 8 ≥16 ≤0.5 ≤0.5 8
Levofloxacin ≤0.12 ≥8 ≥8 4 ≤0.12
Linezolid 2 NT 2 1 1
Norfloxacin NT ≥16 NT NT NT
Nitrofurantoin NT ≤16 ≤16 ≤16 ≤16
Oxacillin ≥4 ≥4 ≥4 ≥4 ≥4
Penicillin G NT ≥0.5 ≥0.5 ≥0.5 ≥5
Rifampicin ≤0.03 ≤0.5 ≤0.5 ≤0.5 ≤0.5
Teicoplanin 4 NT 4 4 4
Tetracycline ≤1 2 2 ≥16 ≤1
Tigecycline ≤0.12 NT ≤0.12 0.5 ≤0.12
Tobramycin NT ≥16 ≥16 ≤1 2
Trimethoprim/
Sulfamethoxazole
80 ≥320 ≤10 ≤10 ≤10
Vancomycin 2 NT 2 1 2
aThe numbers are the MIC values expressed in μg/ml; bNT, Not Tested.
containing TB-CS-NPs, CS-NPs, or free TB at optimal concentra-
tions determined in preliminary experiments (data not shown).
Samples containing only bacteria in the buffer assay were set-up
as controls for cell-viability. All the samples were incubated at
37◦C under agitation for a total of 4 days. After 4 h incubation
and at 24 h intervals, aliquots from the samples were taken, seri-
ally diluted and plated on TSA for CFU counting. Results were
expressed as log10 CFU/ml.
Statistical Analysis
All the characterizations were performed at least on three repli-
cates, unless otherwise specified. The data were statistically ana-
lyzed using Student’s t-test. Statistical significance was set at the
level of ∗p< 0.05.
Results
Preparation and Characterization of
TB-CS-NPs
Chitosan nanoparticles were easily obtained by means of ionic
gelation between cationic CS and anionic TPP, as previously
described (Piras et al., 2015). The formulation parameters (CS
solution pH and concentration, amount of peptide) previously set
for the model peptide RSI were applied to the encapsulation of
TB in CS-NPs. The prepared NP suspensions appeared opales-
cent and without macroscopically appreciable aggregates. The
dynamic light scattering analysis of the prepared NPs revealed
that the loading of TB led to an increase in the NPs average diam-
eter, being the obtained diameters 124± 17 and 185± 10 nm, for
blank and TB-CS-NPs, respectively (Table 2).
Both blank and loaded NPs displayed positive Zeta potential
values in SPB at pH 7.4, due to the cationic nature of CS. The
TB loading led to a statistically significant decrease of the Zeta
potential value.
The TB loading capacity and encapsulation efficacy of CS-NPs,
evaluated by means of Micro BCATM protein assay, are shown in
Table 2. The results obtained revealed a TB loading of 4.8% and
an encapsulation efficacy of 75%. The release kinetics of the pep-
tide from TB loaded NPs was studied in SPB pH 7.4 for 15 days
(Figure 1). After a first equilibration time (lag time), the system
displayed a progressive linear release, according with the results
obtained with the model peptide RSI.
Cytocompatibility Evaluation of TB-CS-NPs
vs. Free TB
The cytocompatibility of free TB and of the developed TB-CS-
NPs was evaluated using mouse embryo fibroblast BALB/3T3
Clone A31 cell line as indicated in the International Standard
ISO 10993- Part 5: “Test for cytotoxicity – in vitro meth-
ods.” In order to investigate the capability of the developed
nanocarrier to limit the toxicity of the loaded TB against
mammalian cells, at first determination of the IC50 of free
FIGURE 1 | Release profile of temporin B from TB-CS-NPs in SPB pH
7.4, 37◦C. After a short lag time, the system displayed a progressive linear
release of the loaded active agent.
TABLE 2 | Main characteristics of plain CS-NPs and TB-CS-NPs: average diameter distribution (Size), yield of the formulations and purification
processes (yield), surface charge (Zeta potential), loading capacity (L), and encapsulation efficiency (EE).
Formulation Size (nm ± SD) PdIa Yield (% ± SD) Zeta potential (mV ± SD) L (% ± SD) EE (% ± SD)
CS-NPs 124 ± 17 0.010 41.4 ± 0.2 +21.9 ± 0.6 – –
TB-CS-NPs 185 ± 10 0.063 43.1 ± 0.1 +8.8 ± 0.1 4.8 ± 0.2 74.7 ± 2.3
aPolydispersity index of the diameter distribution peak.
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TB was assessed. Results showed that TB generated an IC50
value of ∼119 μg/ml after 24 h of incubation (Figure 2A).
Further investigations performed under the same experimen-
tal conditions employing TB loaded into CS-NPs highlighted
a remarkable lower cytotoxicity of the bioactive compound
(Figure 2B). In fact, by comparing the toxicity of different con-
centrations of free TB (116.5, 233, and 466 μg/ml) with the
same amount loaded into CS-NPs, statistically significant differ-
ences on 3T3 cell viability were observed (p < 0.05, Student’s
t-test).
Bactericidal Activity of the Developed
Nanocarrier Against S. epidermidis
Preliminary experiments were carried out in order to identify the
optimal experimental conditions that could allow the assessment
of TB antibacterial activity for prolonged intervals of times (data
not shown). Addition of 1.25% TSB to the buffer assay was found
to be the optimal concentration able to maintain the control bac-
teria alive for all the duration of the experiment, with no effect
on TB antibacterial activity. In addition, a starting inoculum of
approximately 1 × 107 CFU/ml and a concentration of plain CS-
NPs of 5 mg/ml were found to be optimal for monitoring the
bactericidal activity for at least 4 days.
At these optimal conditions, the number of viable bacteria
recovered after exposing the starting inoculum to TB-CS-NPs
(5 mg/ml) for 4 h, 1, 2, 3, and 4 days, was compared to that
obtained exposing the bacteria to plain CS-NPs (5 mg/ml) and to
free TB. Taking into account the data collected from the in vitro
release kinetics, performed under the same conditions of the
bactericidal assays, the releasing rate of 5 mg/ml of TB-CS-NPs
corresponded to 2.5 μg/ml/day. Therefore, the concentration of
free TB (10 μg/ml) used in the bactericidal assay was approx-
imately equal to the total amount of the peptide released by
the loaded nanocarrier over the observational period (4 days).
Bacteria incubated in the medium assay only served as control
of cell-viability.
Figure 3 depicts the kinetics of the bactericidal effect against
the reference strain S. epidermidisATCC35984. At very early time
points (4 h incubation) both CS-NPs and TB-CS-NPs exerted a
modest bactericidal activity, while, as expected, free TB caused
more than 3-log reduction in the number of CFU/ml as com-
pared to not treated bacteria. Starting from 1 day of incubation,
however, residual bacteria that have been exposed to free TB
underwent to a progressive regrowth reaching, within 4 days of
incubation, CFU levels comparable to those of control bacteria.
In contrast, during the same incubation times, the TB-loaded
nanocarrier (TB-CS-NPs) exerted a strong bactericidal activity
against S. epidermidis, causing a statistical significant reduction
in the number of CFU/ml, as compared to both free TB and plain
CS-NPs. At 4 days of incubation, almost 4-log reduction in the
number of viable S. epidermidis compared to plain CS-NPs, and
6-log reduction compared to free TB and control bacteria were
observed.
FIGURE 3 | Kinetics of the antibacterial activity of the developed
nanoparticle-based AMP-delivery system against Staphylococcus
epidermidis ATCC35984. Bacterial cells were exposed for different time
intervals to free TB, CS-NPs, or TB-CS-NPs. At the end of the exposure time
aliquots of the cultures were serially diluted, plated on solid medium, and
incubated at 37◦C for 48 h before assessing the CFU count. Results are the
mean values ± SEM of three independent experiments. CTRL, control
bacteria incubated in the assay medium only. ∗p < 0.05; ∗∗p < 0.01;
∗∗∗p < 0.001 as compared to TB-CS-NPs, Student’s t-test.
FIGURE 2 | Cytocompatibility evaluation of free TB (A) and of TB
loaded into CS-NPs (B) in mouse embryo fibroblast cell line Balb
3T3/Clone A31. (A) Determination of free TB cytotoxicity. Results show
that free TB displays an IC50 value of ∼119 μg/ml after 24 h of
incubation; (B) Comparison of cytotoxicity of different concentrations of
free TB (116.5, 233, and 466 μg/ml) with the same amount loaded into
CS-NPs (TB-CS-NPs), corresponding to TB-CS-NPs concentrations of 2.5,
5, and 10 mg/ml, respectively. Results show a statistically significant
reduction of TB toxicity upon its loading into nanoparticles (∗p < 0.05,
Student’s t-test).
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The antibacterial properties of the TB-CS-NPs as compared
to plain CS-NPs was also tested against four clinical isolates of
S. epidermidis after 4 days of exposure. As depicted in Figure 4,
for three out of four strains, a statistically significant difference
in the CFU number was obtained between plain and TB-loaded
CS-NPs, similarly to what observed with the reference strain.
To test the hypothesis that the mere encapsulation of TB in
CS-NPs could stimulate the antibacterial activity of chitosan, the
peptide RSI was used as a control of the susceptibility assay as
the peptide shares key chemical–physical properties with TB,
but is not endowed with antibacterial activity. A preparation of
RSI-loaded CS-NPs was obtained as previously described (Piras
et al., 2015) and incubated at the concentration of 5 mg/ml for
4 days with S. epidermidisATCC35984 cells. After the incubation
period, the number of bacterial cells that survived the treatment
was assessed and compared to that obtained incubating the same
number of bacteria with plain CS-NPs, free RSI, or medium
only. The number of CFU obtained following incubation with
RSI-loaded CS-NPs was similar to that obtained with plain CS-
NPs (4.1 ± 3 × 104 versus 1.9 ± 0.6 × 104 p > 0.05 Student’s
t-test), suggesting that the entrapment of a cationic peptide do
not enhance, per se, the antimicrobial properties of CS-NPs. As
expected, no killing activity of free RSI was observed (data not
shown).
Discussion
Over the last few years, several nanoparticle-based antibiotic
delivery systems have been developed and are under evaluation
in clinical trials or have reached the market (Gao et al., 2011).
FIGURE 4 | Antibacterial activity of TB-CS-NPs as compared to the
plain nanocarrier against clinical isolates of S. epidermidis after
4 days of incubation. Bacterial cells were exposed for 4 days to plain
CS-NPs or TB-CS-NPs. At the end of the exposure time aliquots of the
cultures were serially diluted, plated on solid medium, and incubated at 37◦C
for 48 h before assessing the CFU count. Results are the mean values ± SEM
of two independent experiments performed in duplicate. CTRL, control
bacteria incubated in the assay medium only. ∗p < 0.05; ∗∗p < 0.01; as
compared to TB-CS-NPs, Student’s t-test.
Nevertheless, a real concern regarding the use of these nanosys-
tems is that their therapeutic potential might be neutralized or
highly reduced by the loss of efficacy of conventional antibiotics
due to the growing rise of multi-drug-resistant microorgan-
isms worldwide. Although bacterial mechanisms of resistance
to AMPs have been described as well (Maisetta et al., 2011;
Guilhelmelli et al., 2013), it is generally agreed that their devel-
opment rate is much lower than that of conventional antibiotics,
making AMPs promising future drugs against different types of
infections (Easton et al., 2009; Batoni et al., 2011).
As the therapeutic efficacy and safety of AMPs administered by
conventional methods is limited, their encapsulation in different
kinds of delivery systems, aimed at improving their therapeuti-
cal potential, is being at the center of considerable attention. To
date, AMPs have been mainly incorporated within micelles, lipo-
somes, lipidic disks, and metal-based nanocomposites (Urbán
et al., 2012; Carmona-Ribeiro and Dias de Melo Carrasco, 2014).
However, over the last years, also numerous biocompatible and
biodegradable polymers, both natural (e.g., alginate, CS, collagen,
gelatin, hyaluronic acid) and synthetic (e.g., polyesters, poly-
carbonates, polyurethanes) have attracted increasing attention
as matrices for the formulation of the AMPs carriers (Sobczak
et al., 2013). Among all polymers, CS appears certainly one of the
most promising to be used in the development of nanostructured
antimicrobial systems because of its inherent antimicrobial prop-
erties and its ability to gel spontaneously on contact with mul-
tivalent polyanions under mild conditions. This feature allows
the encapsulation of labile therapeutic macromolecules, such as
AMPs.
In order to investigate the therapeutic potential of
nanoparticle-based AMP delivery systems, in the present
work TB was encapsulated into CS-NPs and the developed nano-
system was finely characterized in terms of physical–chemical
properties, releasing kinetics, toxicity, and antibacterial efficacy.
The TB-loaded CS-NPs were easily prepared by following
the formulation parameters previously set for the CS-RSI model
NPs (Piras et al., 2015). As expected, the obtained particles had
positive surface charge, nanoscaled diameter and high peptide
loading. Being an amphiphilic cationic peptide, TB is taking part
to the ionotropic gelation in presence of the anionic TPP and the
charge repulsion between cationic CS and cationic TB is reduced
by the selected solution pH. The presence and participation of TB
to the ionotropic gelation may induce conformational and charge
rearrangements of CS that are reflected in a statistically signifi-
cant reduction (p < 0.05, Student’s t-test) of the Zeta potential
value. In agreement with previous studies (Piras et al., 2015), TB
is progressively released by the system and the slope of the linear
section of the release kinetics is comparable to that observed with
the model RSI peptide.
Few examples can be found in the literature of AMPs suc-
cessfully encapsulated in micro/NPs. Recently Chereddy et al.
(2014) prepared PLGA NPs encapsulated with LL-37, with a
mean diameter of 304 nm, by W/O/W emulsion–solvent evapo-
ration technique. The LL-37 is the only human peptide belonging
to the cathelicidin family, has powerful antibacterial activity,
and is an amphipathic cationic helical peptide, features shared
with TB, despite its longer chain (37 aa versus 13 aa of TB).
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The PLGA NPs had a low payload of peptide, 1.02 μg LL37/mg
PLGA NPs, corresponding to 0.1% by weight. The evaluation
of the release kinetics highlighted an initial burst release of LL-
37 from PLGA-LL37 NP, corresponding to nearly 40% of total
amount of loaded peptide within the first day, and reaching 80%
of released peptide by day 14. The antimicrobial activity of the
nanosystem was investigated in vitro against Escherichia coli only
at early times of incubation (6 h), displaying a lower antimicro-
bial activity of the PLGA LL-37 loaded NPs compared to the free
peptide.
In another report, LL-37 was loaded into CS/poly(g-glutamic
acid) MPs with an average diameter of 1.2 mm. The MPs had a
high loading % of LL-37 (40% by weight) as generally expected
from MPs. Furthermore, the peptide was very quickly released,
showing a burst value of 71.2% within the first hour and reaching
a plateau of about 90% of cumulative release after 24 h. Despite
the composite MPs were thought as a multifunctional carrier for
LL-37 and nitric oxide to fight bacterial infections, the antimi-
crobial activity of the developed system was not assessed by the
authors (Sun et al., 2015).
In the present work, the materials and formulation methods
adopted for the loading of TB into CS based NPs allowed the
achievement of a nanosized carrier with noteworthy peptide pay-
load and release kinetics, with no burst effect and slow constant
(linear) release rate.
The in vitro cytocompatibility evaluation of TB-CS-NPs
highlighted the excellent role of the developed nanosystem
in reducing TB toxicity profile toward mammalian cells. This
result corroborates that the undertaken strategy of AMPs encap-
sulation in suitable nanocarriers may improve the potential
of these therapeutic molecules by reducing their toxicity and
enhancing their therapeutic activity by sustained and targeted
delivery.
There are inherent experimental difficulties in the assessment
of antibacterial activity for prolonged intervals of times mainly
due to the fact that, after long incubation times bacterial cells
undergo to spontaneous death because of nutrient limitation.
An accurate evaluation of the different parameters involved was,
therefore, necessary to identify the optimal conditions for the
assessment of the antibacterial activity for prolonged intervals
of times. In particular, the parameters studied included: (i) the
identification of the minimal percentage of growing medium
(TSB), to be added to the buffer assay (SPB, pH 7.4), able to
provide sufficient amount of nutrients to ensure the vitality of
control bacteria for all the observational period. In this regard,
it is noteworthy to point out that antimicrobial activity of AMPs
might be inhibited by the presence of the growth medium in
the bactericidal assay that, therefore, has to be kept to the min-
imum; (ii) the entity of the starting inoculum able to ensure a
detectable number of residual cells after the eventual initial burst;
(iii) the optimal concentration of the empty CS-NPs; such con-
centration had to be high enough to allow the encapsulation of
sufficient amount of TB, but not too high to mask the bacte-
ricidal activity of the released peptide when loaded NPs were
used.
Given an inoculum of 107 bacteria, we found that empty CS-
NPs, used at a concentration of 5 mg/ml, were able to reduce
the inoculum of approximately 2-logs as compared to the con-
trol bacteria incubated in medium only, thus contributing to the
overall antibacterial activity of the nanosystem; in addition, based
on the releasing kinetic studies, 5 mg/ml of TB loaded-CS-NPs
were able to ensure a cumulative release of the peptide of about
10 micrograms in 4 days, corresponding to the TB bactericidal
concentration.
For these reasons, we chose the concentration of 5 mg/ml as,
for the chosen inoculum, it represented the optimal combination
of CS and TB likely to allow both components of the nanosystem
to exert their antimicrobial activity.
Interestingly, at the optimal experimental conditions iden-
tified, the TB-loaded nanocarrier was able to exhibit a strong
antibacterial activity that lasted for all the observational period
(4 days), and was statistically higher than that exerted by the
plain CS-NPs or free TB. This long-lasting antibacterial activity
was demonstrated not only against the S. epidermidis reference
strains, but also against clinical isolates of S. epidermidis high-
lighting the potential of our delivery system as nanotherapeutic
to treat bacterial infections in clinical settings.
The bactericidal action of CS has been widely investigated
in recent years and it has been mainly attributed to its polyca-
tionic nature and consequent ability to interact with the anionic
components of bacterial surface (Kong et al., 2010). This interac-
tion would ultimately lead to membrane permeability, release of
cellular contents and death.
The bactericidal effect of CS is highly dependent on several
factors including its molecular weight and deacetylation degree,
physical state, ionic strength, pH, surface characteristics of tar-
get microorganisms (Dash et al., 2011). Depending on one or
more of these variables, alternative bactericidal mechanisms of
chitosan have been proposed including inhibition of mRNA syn-
thesis and DNA transcription (Sudarshan et al., 1992), chelating
capacity (Rabea et al., 2003), induction of multiple changes in the
expression profiles of genes involved in the regulation of stress,
autolysis, and energy metabolism (Raafat et al., 2008).
Of note, CS-NPs were found to exhibit even a higher antimi-
crobial activity than the free polymer against both Gram-positive
and Gram-bacteria; in this regard it has been proposed that
thanks to their high surface charge density CS-NPsmay be tightly
adsorbed onto the bacterial surface and interact with bacteria to
a greater degree than free chitosan (Qi et al., 2004).
Regarding the mechanism of action of TB, it seems to be
dependent on its interaction with the microbial membranes, sim-
ilarly to what has been demonstrated for many other AMPs
(Mahalka and Kinnunen, 2009; Mangoni and Shai, 2009). The
first step in this interaction is the electrostatic attraction between
the cationic peptide and the negatively charged components of
the bacterial cell wall. After that, the peptide reaches the inner
membrane perturbing its permeability and causing a rapid cell
death. The sharp drop in CFU number observed in our study, fol-
lowing incubation of bacteria with free TB is consistent with the
above mentionedmechanisms of action of the peptide (i.e., bacte-
rial membrane permeabilization). Inactivation of the free peptide
and/or its sequestration by dead bacteria or medium compo-
nents may explain the re-growth of the bacteria that survived the
treatment observed at later times of incubation.
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At the moment, the possible mechanism of the com-
bined antibacterial activities of the TB-loaded CS-NPs devel-
oped in our study is not known. Our hypothesis is that,
besides being bactericidal themselves, CS-NPs may deliver the
encapsulated peptide directly to the bacterial surface mean-
while preventing its inactivation by interaction with medium
components or dead bacteria; release of TB at the bacterial
surface would allow the achievement of a high local concen-
tration of the peptide that could rapidly reach the bacterial
membrane causing cell death. If this was the case, even pep-
tide concentrations below those needed to ensure a bacterici-
dal effect of the free peptide would be sufficient to cause cell
death.
A crucial issue regarding the release of antimicrobial com-
pounds by delivery systems is the releasing kinetics. It is generally
agreed that too fast releasing kinetics may provide a relatively
high initial dose of the active drug, but also potential cytotoxic-
ity and short-term action. In contrast, too slow releasing kinetics
may not ensure the required therapeutic level of the antimicro-
bial compound, increasing the risk of selecting resistant cells
that adapt to the environment. Therefore, an “ideal” antibac-
terial delivery system should exhibit a sufficiently high initial
release rate (burst release) to counter any initial elevated infec-
tion risk, followed by a long period of drug release, within the
therapeutically efficacious dosing zone, to eradicate bacteria that
have survived the initial burst (Hetrick and Schoenfisch, 2006;
Wu and Grainger, 2006). The results obtained from the assess-
ment of the antibacterial activity of the nano-system developed
in our study seem to perfectly match these requirements. In
fact, the antibacterial activity exerted by the nanocarrier itself
(CS-NPs) was able to ensure a “burst” activity within the first
24 h of incubation able to markedly reduce the starting inocu-
lum. Afterward, TB was released in a linear manner by the
nanocarrier and/or directly delivered to the bacterial surface was
able to further reduce the viable count, preventing the regrowth
of the residual cells and ensuring a long-lasting antibacterial
activity.
Antimicrobial peptide delivery through nanocarriers, as the
one developed in this study, has the potential to be employed
in a wide range of applications. Pathological conditions that,
in our opinion, could particularly benefit from the use of such
nanosystems are those that occur at mucosal/skin surfaces and
require multiple (daily) and long term drug administrations
for prevention/treatment of microbial infections. These condi-
tions include pulmonary infections in cystic fibrosis patients or
wound infections in burned or diabetic patients. Besides being
extremely time-consuming for the patients, the therapeutic reg-
imen usually adopted in these conditions may enhance the risk
of resistant mutant selection, contributing to the worldwide
spread of bacterial resistance. The muco-penetrating ability of
chitosan, the low tendency in inducing bacterial resistance of
the delivered AMP, the high cytocompatibility and the strong
antibacterial properties of both components, together with the
continuous releasing kinetics are all properties that could likely
contribute to the long-lasting control of microbial infections
in the above mentioned conditions, meanwhile reducing the
number of drug administrations and increasing the patient’s
compliance.
In our study S. epidermidis was used as model Gram-positive
bacterium. TB has previously shown activity also against a
broad range of nosocomial Gram-positive and, to a lesser extent,
Gram-negative species/strains (Mangoni et al., 2008). TB-analogs
with improved activity against Gram-negative species have been
recently described (Avitabile et al., 2013; Bezzerri et al., 2014).
Thus, the nanocarrier described herein may represent a versatile
tool to allow a long-term control of microbial infections sustained
by different clinically relevant bacterial species.
Conclusion
Research on the development of AMPs as new drugs may largely
benefit from the use of nanotechnologies, hopefully allowing to
overcome the limits that still hamper AMPs’ clinical use.
In the present work, we carried out a first characterization
in vitro of a nanoparticle-based delivery system for AMPs with
the aim to demonstrate the potential of such system in ensur-
ing prolonged and strong bactericidal activity against a model
bacterial species. In particular, we demonstrated that loading of
TB, chosen as a model cationic alpha-helical AMP, in CS-NPs
represents a promising and innovative strategy to ensure a long-
lasting bactericidal activity against the clinically relevant species
S. epidermidis. The results obtained also demonstrated that the
nanocarrier itself contributed to the overall antibacterial activ-
ity of the developed nanosystem, allowing the achievement of
an optimal killing kinetics, and reducing, at the same time, the
toxic potential of the loaded peptide. In vivo/ex vivo studies will
be needed to fully evaluate the ability of the developed nanosys-
tem in preventing/treating infections occurring at mucosal/skin
surfaces and in increasing the translational potential of promising
peptide molecules.
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